苏州纳微科技股份有限公司（以下简称"公司"）2026 年第一次职工代表大 会于 2026 年 1 月 26 日召开，就公司拟实施的 2026 年员工持股计划（以下简称 "本次持股计划"）征求公司职工代表意见。本次会议的召集、召开及表决程序 符合有关法律法规以及企业民主管理相关规定，会议决议合法有效。 证券代码：688690 证券简称：纳微科技 公告编号：2026-004 苏州纳微科技股份有限公司 2026年第一次职工代表大会会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、职工代表大会会议召开情况 职工代表大会审议通过《苏州纳微科技股份有限公司 2026 年员工持股计划 （草案）》及其摘要的相关内容。 2026 年员工持股计划尚需提交公司股东会审议通过后方可实施。 特此公告。 苏州纳微科技股份有限公司董事会 2026年1月27日 二、职工代表大会会议审议情况 经与会职工代表认真讨论，投票表决，形成如下决议： 与会职工代表认为公司 2026 年员工持股计划遵循依法合规、自愿参与、风 险自担、资金自筹的基本原则 ...

证券简称：纳微科技 证券代码：688690 苏州纳微科技股份有限公司 2026 年员工持股计划 （草案） 苏州纳微科技股份有限公司 二零二六年一月 风险提示 1、本持股计划需公司股东会审议通过后方可实施，本持股计划能否获得公 司股东会批准，存在不确定性。 2、有关本持股计划的具体实施方案属初步结果，能否完成实施，存在不确 定性。 3、员工遵循依法合规、自愿参与、风险自担原则参与本持股计划。若员工 认购资金较低，则本持股计划存在不成立或者低于预计规模的风险。 4、公司后续将根据规定披露相关进展情况，敬请广大投资者谨慎决策，注 意投资风险。 -2- 特别提示 1、《苏州纳微科技股份有限公司 2026 年员工持股计划（草案）》（以下简 称"持股计划"）系苏州纳微科技股份有限公司（以下简称"本公司"、"公 司"、"纳微科技"）依据《中华人民共和国公司法》《中华人民共和国证券法》 《关于上市公司实施员工持股计划试点的指导意见》《上海证券交易所科创板上 市公司自律监管指引第 1 号——规范运作》等有关法律、行政法规、规章、规范 性文件和《公司章程》的规定制定。 2、本持股计划遵循依法合规、自愿参与、风险自担的原则，不存在 ...

证券代码：688690 证券简称：纳微科技 公告编号：2026-002 苏州纳微科技股份有限公司 2026年员工持股计划草案摘要公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 预计参与员工持股计划对 | 预计参与对象范围：董事（不含独立董事）、高级管 | | --- | --- | | 象范围及人数 | 理人员、核心技术人员及骨干员工 | | | 预计参与人数：不超过 260 人 | | | 是否有董事、高管、核心技术人员参与认购是 □ | | 董事、高管、核心技术人员 | 否 | | 参与认购情况 | 董事、高管、核心技术人员参与认购人数：9 人， | | | 认购份额占比：9.11% | | 员工持股计划资金来源及 | □员工薪酬 | | 规模 | 自筹资金 | | | □其他方式： | | 员工持股计划股份来源及 | 公司回购股票：规模不超过 3,066,622 股，约占 | | | 当前公司股本总额 403,814,765 股的 0.76% | | 预计规模 | □二级市场购买 | | ...

（四） 现场会议召开的日期、时间和地点 证券代码：688690 证券简称：纳微科技 公告编号：2026-005 苏州纳微科技股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2026年第一次临时股东会 网络投票起止时间：自2026 年 2 月 12 日 至2026 年 2 月 12 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 股东会召开日期：2026年2月12日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 召开日期时 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 苏州纳微科技股份有限公司（以下简称"公司"）第三届董事会第十三次会 议于 2026 年 1 月 26 日以线上线下相结合的方式召开。本次会议由董事长江必旺 博士主持，应出席董事 9 人，实际出席董事 9 人。本次会议的召集和召开程序、 出席人员的资格和议案审议程序均符合《中华人民共和国公司法》等法律法规和 《苏州纳微科技股份有限公司章程》等相关规定，会议形成的决议合法、有效。 二、董事会会议审议情况 会议由董事长江必旺召集和主持，审议并一致形成了以下决议： 证券代码：688690 证券简称：纳微科技 公告编号：2026-003 苏州纳微科技股份有限公司 第三届董事会第十三次会议决议公告 （一）审议通过《关于公司<2026 年员工持股计划（草案）>及其摘要的议 案》 表决结果：通过。 具体内容详见公司同日刊登在上海证券交易所网站（www.sse.com.cn）的 《苏州纳微科技股份有限公司 2026 年员工持股计划（草案）》及《苏州纳微科技 股份有限公司 ...

苏州纳微科技股份有限公司第三届董事会薪酬与考核委员会关于公司2026年员工持股计划相关事项的核查意见 苏州纳微科技股份有限公司 五、公司实施本持股计划有利于建立和完善员工与全体股东的利益共享机制， 使员工利益与公司长远发展更紧密地结合，有利于提高员工的凝聚力和公司竞争 力，充分调动员工的积极性和创造性，吸引和保留优秀管理人才和业务骨干，实现 公司可持续稳健发展。 综上，董事会薪酬与考核委员会同意公司实施本持股计划，并同意将本持股计 划相关议案提交公司董事会审议。关联委员江必旺博士拟认购本持股计划份额，已 1 苏州纳微科技股份有限公司第三届董事会薪酬与考核委员会关于公司2026年员工持股计划相关事项的核查意见 回避表决。 关于公司2026年员工持股计划相关事项的核查意见 苏州纳微科技股份有限公司（以下简称"公司"）董事会薪酬与考核委员会根 据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》 （以下简称"《证券法》"）《关于上市公司实施员工持股计划试点的指导意见》（以 下简称"《指导意见》"）《上海证券交易所科创板上市公司自律监管指引第 1 号—— 规范运作》（以下简称"《自律监管指引第 ...

Investment Rating - The industry investment rating is "Recommended" (maintained) [1] Core Viewpoints - The new materials sector is a crucial direction for the future development of the chemical industry, currently experiencing rapid growth in downstream demand. With policy support and technological breakthroughs, domestic new materials are expected to accelerate their long-term growth. The report emphasizes that "one generation of materials leads to one generation of industries," highlighting the foundational nature of the new materials industry as the material basis for other industries [4][15]. Summary by Relevant Sections 1. Electronic Information Sector - Focus areas include semiconductor materials, display materials, and 5G materials [5]. - Recent developments include TSMC's plan to increase investment in advanced packaging technology, aiming to upgrade existing InFO equipment and establish a new WMCM production line, with a target capacity of approximately 60,000 wafers per month by the end of 2026 [6][40]. 2. Aerospace Sector - Key materials of interest are PI films, precision ceramics, and carbon fibers [7]. - The successful launch of the Long March 12 rocket, which deployed 19 low-orbit satellites, demonstrates the capabilities of China's aerospace technology [8][50]. 3. New Energy Sector - Focus areas include photovoltaics, lithium-ion batteries, proton exchange membranes, and hydrogen storage materials [9]. - By the end of 2025, China's power storage capacity is projected to reach 213.3 GW, a year-on-year increase of 54%, with new energy storage accounting for over two-thirds of this capacity [10]. 4. Biotechnology Sector - Key areas include synthetic biology and scientific services [11]. - Significant advancements in agricultural biotechnology were reported, including breakthroughs in crop genetic improvement and the development of new wheat varieties [12]. 5. Energy Conservation and Environmental Protection Sector - Focus areas include adsorption resins, membrane materials, and biodegradable plastics [13]. - The government has initiated projects to support equipment upgrades across various sectors, with a total investment exceeding 460 billion yuan [14]. 6. Key Companies and Profit Forecasts - The report highlights several key companies with their respective stock prices and earnings per share (EPS) forecasts for 2023 to 2025, indicating a generally positive outlook for the new materials sector [16].

Investment Rating - The report maintains a positive investment rating for the pharmaceutical sector [6] Core Insights - The pharmaceutical sector experienced a week-on-week decline of 0.68%, underperforming compared to the ChiNext and CSI 300 indices, ranking 17th among all industries [2][36] - The report emphasizes the importance of innovation, international expansion, and overcoming challenges as key themes for investment in 2026, with a focus on BD 2.0, small nucleic acids, and supply chain opportunities [3][4] - The upcoming adjustment of the National Essential Drug List is seen as critical, aiming to address clinical needs that have evolved since the last update in 2018, particularly in pediatrics, oncology, and rare diseases [5][14] Summary by Sections National Essential Drug List Adjustment Analysis - The current drug list has not been updated since 2018, leading to a disconnect with clinical needs, necessitating a systematic adjustment [14] - The adjustment will focus on filling gaps in disease coverage, particularly in pediatrics, oncology, and rare diseases, while also solidifying the integration of collective procurement and national negotiation outcomes [18][19] - The report identifies potential beneficiaries in traditional Chinese medicine, particularly in areas with previously weak coverage [28] JP Morgan Conference Overview - The 44th JP Morgan Health Conference highlighted strategic developments from major global pharmaceutical companies, showcasing their core pipeline advancements and key clinical milestones for 2026 [33] - Companies like Pfizer, Merck, and Eli Lilly presented their focus on innovative treatments and upcoming clinical trials, indicating a robust pipeline for future growth [34][35] Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance in early 2026 has shown a 7.08% increase, outperforming both the CSI 300 and ChiNext indices [36] - The report notes a shift in market sentiment, with certain innovative sectors like AI healthcare and medical robotics showing strong performance, while traditional sectors faced adjustments [2][3]

Investment Rating - The report maintains a "Hold" rating for the pharmaceutical sector [6] Core Insights - The pharmaceutical sector experienced a week-on-week decline of 0.68%, underperforming both the ChiNext Index and the CSI 300 Index, ranking 17th among all industries [2][36] - The report emphasizes a positive outlook for innovation, international expansion, and turnaround opportunities in the pharmaceutical industry, with a focus on BD 2.0, small nucleic acids, and supply chain [3][4] Summary by Sections 1. National Essential Drug List Adjustment Analysis - The adjustment of the National Essential Drug List is urgent as the current version has not been updated since 2018, leading to a disconnect with current clinical needs [14] - The new adjustments will focus on three main areas: addressing gaps in disease coverage, solidifying the integration of centralized procurement and national negotiation results, and enhancing the evidence-based standards for traditional Chinese medicine [5][14] - Potential beneficiaries from the adjustments include companies like Panlong Pharmaceutical, Guizhou Sanli, and Yiling Pharmaceutical, particularly in pediatrics, orthopedics, and cardiovascular fields [5][28] 2. JP Morgan Conference Overview - The 44th JP Morgan Health Conference highlighted strategic developments from major global pharmaceutical companies, showcasing their core pipeline progress and key clinical milestones for 2026 [33] - Companies such as Pfizer, Merck, and Eli Lilly presented their focus on advancing clinical trials and launching new products in various therapeutic areas [34][35] 3. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance from January 12 to January 16 showed a decrease of 0.68%, with a total trading volume of 916.83 billion yuan, accounting for 5.35% of the total market [2][36] - The report notes that the sector has shown a year-to-date increase of 7.08%, outperforming both the CSI 300 and ChiNext indices [36]

Core Insights - The Chinese nanosphere industry is experiencing rapid growth, with a projected market size of approximately 4.236 billion yuan in 2024, representing a year-on-year increase of 5.40% [2][11] - Nanospheres are critical materials in high-tech products, serving as essential components in biomedicine and flat panel displays, thus being referred to as "behind-the-scenes heroes" and "bottleneck" materials [2][11] Industry Overview - Nanospheres are micron-sized spheres with nanometer-scale pore structures, characterized by high specific surface area and unique physicochemical properties, widely used in drug delivery, LCD displays, bioseparation, medical diagnostics, and optoelectronic materials [2] - They can be classified into natural biomaterials (e.g., chitosan, collagen) and synthetic polymers (e.g., PLGA, PVA) [4] Preparation Methods - Nanospheres can be prepared using various methods, including ionic crosslinking, emulsification-solvent evaporation, and microfluidic technology, each with distinct principles, applicable materials, and performance characteristics [5][7] - Ionic crosslinking is suitable for natural biomaterials and emphasizes biocompatibility, while emulsification-solvent evaporation is widely used for synthetic polymers, and microfluidic technology allows for precise control of droplet formation [7] Industry Chain - The upstream of the nanosphere industry includes raw materials such as chitosan, starch, cellulose, and various synthetic polymers, along with production equipment like high-pressure homogenizers and laser particle size analyzers [8][9] - The midstream involves the manufacturing of nanospheres, while the downstream applications include drug delivery, biopurification, in vitro diagnostics, LCD spacers, and conductive materials [8] Market Size - The market for nanospheres in China is projected to grow significantly, with the biomedicine sector utilizing uniform-sized, surface-modifiable nanospheres for high-end drug development and precise diagnostics [11]